IGC Pharma, Inc.IGCNYSE
Loading
Year-over-year operating income growth rate
Percentile
P23
Within normal range
vs 5Y Ago
-4x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -52.18% |
| Q2 2025 | -34.92% |
| Q1 2025 | 24.81% |
| Q4 2024 | -6.70% |
| Q3 2024 | 26.54% |
| Q2 2024 | -10.41% |
| Q1 2024 | 27.62% |
| Q4 2023 | -20.35% |
| Q3 2023 | -16.46% |
| Q2 2023 | 47.04% |
| Q1 2023 | -77.30% |
| Q4 2022 | 8.44% |
| Q3 2022 | 11.21% |
| Q2 2022 | 56.90% |
| Q1 2022 | -172.58% |
| Q4 2021 | 45.15% |
| Q3 2021 | -98.18% |
| Q2 2021 | 21.39% |
| Q1 2021 | -19.99% |
| Q4 2020 | -38.78% |
| Q3 2020 | 13.21% |
| Q2 2020 | 20.96% |
| Q1 2020 | -45.59% |
| Q4 2019 | -30.28% |
| Q3 2019 | 11.48% |
| Q2 2019 | 14.31% |
| Q1 2019 | -82.97% |
| Q4 2018 | -8.54% |
| Q3 2018 | -67.09% |
| Q2 2018 | 28.33% |
| Q1 2018 | -50.83% |
| Q4 2017 | -79.99% |
| Q3 2017 | 33.63% |
| Q2 2017 | 46.01% |
| Q1 2017 | -90.16% |
| Q4 2016 | 29.82% |
| Q3 2016 | -72.41% |
| Q2 2016 | 81.93% |
| Q1 2016 | -370.67% |
| Q4 2015 | 26.18% |